Serum Catestatin Level as a Stratification Assessment Tool in Non-Critical COVID-19 Patients

Ivan Jerkovic, Vedran Kovacic (), Tina Ticinovic Kurir, Josko Bozic and Leida Tandara
Additional contact information
Ivan Jerkovic: Department for Urgent and Intensive Medicine with Clinical Pharmacology and Toxicology, Internal Medicine Clinic, University Hospital Split, University of Split School of Medicine, 21000 Split, Croatia
Vedran Kovacic: Department for Urgent and Intensive Medicine with Clinical Pharmacology and Toxicology, Internal Medicine Clinic, University Hospital Split, University of Split School of Medicine, 21000 Split, Croatia
Tina Ticinovic Kurir: Department of Endocrinology, Internal Medicine Clinic, University Hospital Split, University of Split School of Medicine, 21000 Split, Croatia
Josko Bozic: Department of Pathophysiology, University of Split School of Medicine, 21000 Split, Croatia
Leida Tandara: Department of Medical Laboratory Diagnostics, University Hospital Split, University of Split School of Medicine, 21000 Split, Croatia

IJERPH, 2023, vol. 20, issue 2, 1-11

Abstract: Introduction: Catestatin (CST) is a peptide with immunomodulatory, anti-inflammatory, and anti-microbial activities. There are only a few studies that have investigated plasma CST levels in COVID-19 patients (mostly in ICU patients). In our work, the aim was to demonstrate serum CST levels and their correlation with clinical outcomes in a group of severe COVID-19 patients admitted to the non-ICU department. Methods: The subjects were 32 patients (25 females, 7 males) admitted to the non-ICU unit for COVID-19 patients. Results: CST levels in our cohort were higher (8.91 ± 7.00) than previously reported CST levels in control subjects. We found a significant positive correlation between serum CST levels and C-reactive protein (r = 0.423, p = 0.008), D-dimers (r = 0.395, p = 0.013), hsTNT (high-sensitivity troponin T) (r = 0.603, p < 0.001), proBNP (N-terminal pro-brain natriuretic peptide) (r = 0.569, p < 0.001), and hospitalization days (r = 0.388, p = 0.014). There was a difference between groups of participants with SOFA <3 ( n = 18) and SOFA >=3 ( n = 14) in catestatin serum levels (7.25 ± 3.66 vs. 11.05 ± 9.52 ng/mL), but the difference was statistically insignificant ( p = 0.065). Conclusion: We considered plasma CST level at hospital admission as a possible tool for early risk assessment in non-critical COVID-19 patients. This study is an attempt to clarify the complex pathophysiological mechanisms present in the development of severe forms of SARS-CoV2 infection.

Keywords: catestatin; SARS-CoV-2 infection; COVID-19 (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2023
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/20/2/1136/pdf (application/pdf)
https://www.mdpi.com/1660-4601/20/2/1136/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:20:y:2023:i:2:p:1136-:d:1029245

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().